Hindustan Foods Ltd Q3 FY2023 Concall Summary

Key Takeaways

• Record Q4 expected, Q3 muted: QoQ growth was flat as existing plants ran stable and ice-cream/beverage facilities hit their lean season, but management called Q4 a likely record quarter on the back of those same facilities ramping up.
• Baddi is the biggest bet yet: The ₹156 crores Reckitt Benckiser OTC pharma plant acquisition, with US FDA and MHRA certifications, is HFL's largest ever and adds a "slightly more sweetened" margin profile, though closing is 6–8 months away.
• FMCG demand stress is real and unrelieved: Management sees no on-ground action to back a near-term turnaround, with rural demand still stressed per all major customers, which tempers new capacity expansion plans.
• Diversification is the strategy, specialization can wait: For the next 2–3 years, HFL will pursue growth agnostic of product category and location, deferring any split or specialization until opportunities dwindle.
• What to watch next quarter: Whether the ice-cream and beverage ramp-up delivers the promised record Q4, any progress on Baddi regulatory approvals, and any sign that FMCG customer commentary shifts from hope to action.

The Baddi Acquisition: Pharma Entry

• Asset profile: Acquired from Reckitt Benckiser on a going-concern basis, the Baddi plant manufactures OTC medicines, ointments, creams, strips, liquids, syrups, tablets, liquid handwash and plaster, and holds both US FDA and MHRA certifications.
• Deal structure: Cash consideration of ₹156 crores, subject to closing adjustments, with a long-term supply agreement expected; the existing site team and senior management will join HFL, replicating the IGK integration playbook.
• Timeline uncertainty: Control has not yet transferred; acquiring industrial land in Himachal Pradesh requires state government permissions, and past experience suggests a 6-to-8-month wait.
• Capacity and customer mix: Roughly 60% of capacity is spoken for by the anchor tenant; the balance 40% is free and will require HFL to go out and win new customers, with lozenges capacity already fully committed.
• Margin potential, unguided: Management expects margins on the free capacity to be better than current corporate levels because of the complexity and regulatory barriers, but is "very, very reluctant" to give any guidance on how quickly new customers will be signed or what products they will bring.
• Regulated market access: The site already supplies regulated markets in the US and Europe; some product categories are exported, and HFL hopes to attract additional business, though all products are OTC, not ethical or prescription pharmaceuticals.

Sameer Kothari: "This one is slightly more sweetened, because the complexity of the product, both in terms of regulations as well as manufacturing cost assets, as well as GMP, hygiene, et cetera, as a factory, are slightly more sophisticated than some of the other products that we make."

Demand Environment: FMCG Stress

• Volume growth is stressed: All major customers are on record that rural demand continues to be stressed, and this is affecting their plans for new capacity expansion, though HFL's contract manufacturing model has been relatively shielded.
• No on-ground turnaround yet: Management is hoping for improvement in the next couple of months but is not actually seeing action on the ground to back that statement or any imminent turnaround.
• Pet food enthusiasm cools: The category grew rapidly during and after COVID but numbers have cooled down; customer enthusiasm for pet food manufacturing capacity has reduced, and a small private-label D2C project will be a rounding error in overall numbers.
• Guidance restraint: Management explicitly does not want to overcommit to the market and then fall short because of macroeconomic conditions completely outside its control, so it is holding back tangible financial pipeline numbers.

Sameer Kothari: "Right now, I'm not sure we are actually seeing action on the ground to back that statement or to back that turnaround. But all of us are hoping that things will start improving in the next couple of months."

Capacity Ramp-Up: Ice Cream, Beverages & Soap

• Ice cream: The Lucknow facility's first phase was commercialized in April last year but ramped too late to capture the full season; the second phase is slated to start commercial production in March 2023, and production for the current season began in the first week of February.
• Beverages: The experiment has not worked out in the last couple of years, but management remains "very confident" it will work out in the next couple of years and expects the facility to start delivering from this quarter.
• Soap bar project (Hyderabad): Will start operations from the next quarter, effectively giving an annual run rate of ₹3,000 crores plus starting from Q1 or late Q1 of the next financial year.
• Q4 trajectory: On the back of beverages and ice cream ramp-up, Q4 is expected to be a record quarter and "much better" than Q3, though management is reluctant to give specific numbers.

Strategic Posture: Agnostic Growth Now, Specialization Later

• Category and location agnosticism: For the next 2–3 years, HFL will continue to pursue opportunities across product categories and locations without being choosy, driven by the volume of opportunities and the shift toward contract manufacturing.
• Specialization deferred: Management believes contract manufacturers will eventually need to specialize in particular categories or products, but does not see that happening in the next few years; when opportunities dwindle, it will consider specialization or even splitting the company into three product categories.
• OTC pharma and cosmetics with therapeutic claims: Identified as a large category more than a year ago; the couple of acquisitions lined up are believed to serve HFL well in the next couple of years.
• Ice cream ambition: Management sees a huge opportunity for manufacturing ice creams in India and is "very aggressively" trying to look at it.

Sameer Kothari: "I think for the next couple of years, at least 2 to 3 years, we will continue to see this kind of disproportionate growth for us across product categories. And right now, given the growth and given the opportunities that we are getting, I really don't see us being choosy about it."

Integration & Subsidiary Updates

• RB Scholl: Acquisition closed and the entire amount paid to sellers; the name is in the process of being changed to HFL Healthcare.
• Scholl customer transition: The customer (Reckitt to Scholl wellness company) is in the process of transitioning and recently started a partnership or JV with an Indian company, intending to launch those products in India.
• HFL Consumer (ice cream subsidiary): A new company set up to leverage the new tax regime, manufacturing ice creams in Lucknow; possibly posted a loss in the last financial year, which would explain a ₹24 crores revenue / ₹12 lakhs net loss disclosure, though management could not confirm this on the call and promised to revert.
• Pharma team build-out: The top management team for pharma was built nearly 1.5 years ago, in advance of the Baddi and IGK acquisitions.

Guidance & Commitments

Key Metrics